Emile Nuwaysir, Ph.D., serves as BlueRock’s president and CEO. He possesses deep knowledge of the stem cell therapeutics space, and brings more than 15 years of experience cultivating innovative life science companies that are fueled by cutting-edge technologies. In addition, Dr. Nuwaysir helped guide and shape these companies from startup stages to their ultimate successful exits and integration into their global acquirers. Dr. Nuwaysir previously served as president and COO of Cellular Dynamics International (CDI) – A Fujifilm Company, and played an integral part in growing CDI and their stem cell therapy efforts from a pre-revenue startup to a NASDAQ-traded firm that was acquired by Fujifilm Holdings for $307 million in 2015. He was also president of Opsis Therapeutics Inc., CDI’s ocular cell therapy subsidiary. Prior to CDI, Dr. Nuwaysir worked for NimbleGen Systems. He was the first employee hired at the company, and served in various roles of increasing scientific and managerial responsibility, including VP of business development, and group leader of molecular R&D. As a member of the senior management team, he helped orchestrate a dual-track IPO process leading to the company’s acquisition by Roche Diagnostics for $273 million. After the acquisition, he served as CTO and SVP of program management at Roche NimbleGen, where he oversaw product portfolio and lifecycle management for Roche NimbleGen products, managed all business development activities, and led an R&D team in optical, mechanical and fluidics engineering, bioinformatics, molecular biology, photochemistry and software development. Dr. Nuwaysir is vice chairman of Invenra Inc., an antibody discovery company he founded in 2011. He has held Postdoctoral Fellowships at the National Institutes of Health, and the University of North Carolina-Chapel Hill. He holds a B.A. from the University of Delaware, and a Ph.D. in molecular toxicology with a focus in oncology from the University of Wisconsin at Madison.